Becton, Dickinson and Co. (BDX – Q2FY20) – Strong growth across business segments led to progress in Q2FY20.

in , on July 31, 2020

Becton, Dickinson and Company completed the acquisition of Straub Medical, which will further expands the company’s portfolio with a proven device with that’s approved with dual indications for arterial atherectomy and thrombectomy in the U.S. It has solid existing sales in Europe and China. The company is leveraging their strong existing channel and expertise in endovascular technology as they bring this product to the U.S. and accelerate existing sales around the world.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q2FY20 Results – Overview
– Q2FY20 – Geographic Revenues
– Q2FY20 – Segment Performance
– FY20 – Planned Product Launches
– FY20 Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

Crispidea Coverage

No of Pages : 42

Release Information

  • Released

    July 31, 2020

  • Last Updated

    July 31, 2020